Status:
COMPLETED
Clinical Trial Nuedexta in Subjects With ALS
Lead Sponsor:
Center for Neurologic Study, La Jolla, California,
Collaborating Sponsors:
ALS Association
State University of New York - Upstate Medical University
Conditions:
Amyotrophic Lateral Sclerosis (ALS)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether Nuedexta is effective in the treatment of symptoms (impaired speech, swallowing, and saliva control)associated with Amyotrophic Lateral Sclerosis (ALS...
Detailed Description
Muscle weakness, the cardinal feature of ALS, leads to progressive loss of motor function affecting the limbs, tongue, respiratory and pharyngeal muscles. Symptomatic treatments such as the placement ...
Eligibility Criteria
Inclusion
- ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria
- Age 18 years or older
- Exhibits bulbar dysfunction manifested by dysarthria and/or dysphagia, according to PI judgment, exhibits a score of 55 or above on the CNS-Bulbar Function Scale
- Capable of providing informed consent and following trial procedures
- Geographic accessibility to the site
- Women must not be able to become pregnant for the duration of the study and must be willing to be on two contraceptive therapies
- Slow vital capacity (SVC) measure ≥50% of predicted for gender, height, and age at the screening visit
- Must be able to swallow capsules throughout the course of the study, according to PI judgment
- Subjects must not have taken riluzole for at least 30 days or be on a 50mg BID dose of riluzole for at least 30 days prior to randomization (subjects how have never taken riluzole are permitted in the study)
- Subjects taking anti-sialorrhea medication(s) must be on a stable dose for at least 30 days prior to randomization (anti-sialorrhea naïve subjects are permitted in the study)
- Must be able to safely swallow at least 30 milliliters (mLs) of water for the water swallowing test
Exclusion
- Prior use of Nuedexta®
- Current use of dextromethorphan, quinidine, quinine, mefloquine or opioids
- History of quinidine, quinine, or mefloquine-induced thrombocytopenia, hepatitis, or other hypersensitivity reactions
- History of known sensitivity or intolerability to dextromethorphan
- Use of an mono amine oxidase inhibitor (MAOI) or within 14 days of stopping an MAOI
- Prolonged QT interval, congenital long QT syndrome, history suggestive of torsades de pointes, or heart failure
- Complete atrioventricular (AV) block without implanted pacemaker, or subjects at high risk of complete AV block
- Concomitant use with drugs that both prolong QT interval and are metabolized by cytochrome P 2D6 (CYP2D6) (i.e., thioridazine or pimozide)
- Exposure to any other experimental agent (off-label use or investigational) within 30 days prior to Baseline Visit
- Invasive ventilator dependence, such as tracheostomy
- Any history of either substance abuse within the past year, unstable psychiatric disease, cognitive impairment, or dementia, according to PI judgment
- Placement and/or usage of feeding tube
- Pregnant women or women currently breastfeeding
- Unable to turn diaphragm pacing device off during swallowing tests
- Salivatory Botox within 90 days (3 months) of screening
- Salivatory radiation within 180 days (6 months) of screening
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT01806857
Start Date
April 1 2013
End Date
March 1 2015
Last Update
March 24 2017
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
California Pacific Medical Center
San Francisco, California, United States, 94115
2
Georgetown University Medical Center
Washington D.C., District of Columbia, United States, 20007
3
Saint Mary's Health Care
Grand Rapids, Michigan, United States, 49503
4
Hennepin County Medical Center
Minneapolis, Minnesota, United States, 55415